Voluntary Limits on Antibacterial Discharges Increase As Fear of Resistance Grows
Date
22 November 2021
The Benchmark's findings on pharmaceutical companies' manufacturing practices is the focus of an in-depth report by Pink Sheet.
The article explores the data and analysis from the 2021 Antimicrobial Resistance Benchmark, which looks at how companies dispose of wastewater that contains active pharmaceutical ingredients (APIs) – and whether manufacturing sites along the whole supply chain are compliant with discharge limits.
The Access to Medicine Foundation's researcher Martijn van Gerven told the publication that one reason why waste management technology wasn't more widely used by suppliers was cost, adding: "Another reason, from our perspective, is that no one is asking them to. We really want companies to ask them. And I think that's where we can start."
Read the full article on the Pink Sheet website (paywall).